학술논문
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
Document Type
Journal
Author
Arance, Ana; De La Cruz-Merino, Luis; Petrella, Teresa M.; Jamal, Rahima; Ny, Lars; Carneiro, Ana; Berrocal, Alfonso; Marquez-Rodas, Ivan; Spreafico, Anna; Atkinson, Victoria; Svedman, Fernanda Costa; Mant, Andrew; Khattak, Muhammad A.; Mihalcioiu, Catalin; Jang, Sekwon; Cowey, C. Lance; Smith, Alan D.; Hawk, Natalyn; Chen, Ke; Diede, Scott J.; Krepler, Clemens; Long, Georgina, V
Source
Subject
Language
English
ISSN
15277755